Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 613

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 613
---
 —  
     2,900,904 
  
    IPO tradeable 
     2,326,835  
     3.06  
     (725,580) 
     1,601,255 
  
    IPO non-tradeable 
     3,015,464  
     3.06  
     (311,006) 
     2,704,458 
  
    Direct offering March 8, 2024 
     1,600,000  
     1.64  
     (1,066,667) 
     533,333 
  
    Placement agent direct offering March 8,
    2024 
     32,000  
     1.64  
     —  
     32,000 
  
    Inducement/direct offering August 5, 2024 
     1,752,082  
     1.50  
     —  
     1,752,082 
  
    Placement agent direct offering August 5,
    2024 
     49,862  
     1.50  
     —  
     49,862 
  
    Direct offering October 21, 2024 
     2,662,782  
     1.50  
     —  
     2,662,782 
  
    Placement agent direct
    offering October 21, 2024 
     61,448  
     1.50  
     —  
     61,448 
  
    Balance at December
    31, 2024 
     14,401,377  
    $2.95  
     (2,103,253) 
     12,298,124 

    F-15

Note
15. INCOME TAXES

Deferred
tax assets and valuation allowance

The
Company had, subject to limitation, approximately $31 million of net operating loss carryforwards at December 31, 2024, of which approximately
$0.67 million will begin expiring in 2034. The remaining balance of approximately $30 million will carry forward indefinitely. A 100%
valuation allowance has been provided for the deferred tax benefits resulting from the net operating loss carryover due to a lack of
earnings history. In addressing the realizability of deferred tax assets